Close Menu

product launch

The company is positioning the blood-based test as an alternative to invasive chorionic villus sampling, the current standard in Denmark.

The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.

Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.

With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.

The lab-based test allows for the semi-quantitative automatable detection of SARS-CoV-2 nucleocapsid protein on a large scale.

Called the COVID Bubble Test, the UK-based service allows the testing of up to 10 people on a single cartridge for £100, or £10 per person.

The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.

The quantitative kit applies a recombinant S1 subunit of the coronavirus spike protein to detect IgG antibodies against the coronavirus.

The assay uses mass spec to measure levels of three proteins in blood and could provide a low cost, non-invasive alternative to existing Alzheimer's tests.

The assay should have a CE-IVD mark by November and will serve the Finnish molecular diagnostics firm's growing European client base.